Patent application number | Description | Published |
20090214643 | IMPROVED PHARMACOKINETIC PROFILE OF BETA-ADRENERGIC INVERSE AGONISTS FOR THE TREATMENT OF PULMONARY AIRWAY DISEASES - Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled-release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release of the beta-adrenergic inverse agonist resulting in a pharmacokinetic profile that minimizes acute detrimental reduction in airway function with the first dose and with each successive dose. This pharmacokinetic profile typically results in slow release of the drug into the bloodstream resulting in a large average T | 08-27-2009 |
20110171132 | Methods, Compounds, and Compositions for Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition. | 07-14-2011 |
20130156703 | Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition. | 06-20-2013 |
20150017150 | Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract - The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition. | 01-15-2015 |
Patent application number | Description | Published |
20100016207 | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid - The present invention provides methods of increasing the level or release of gamma aminobutyric acid (GABA) in the brain, treating Alzheimer's disease, Huntington's disease, symptoms thereof, anxiety, aggression, insomnia, cognitive or memory disturbances; seizures of any cause (e.g. idiopathic epilepsy), primary or metastatic brain tumors, depression (e.g. bipolar depression), or pain (e.g. neuropathic pain), comprising administration of glutamine, a salt thereof, or a glutamine-rich peptide. The present invention also provides methods for decreasing the level or release of GABA in the brain and treating hepatic encephalopathy, depressed consciousness, and coma, comprising decreasing dietary intake of glutamine. | 01-21-2010 |
20100022567 | Compositions containing pufa and/or uridine and methods of use thereof - This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, and/or uridine, a metabolic precursor thereof, or a combination thereof. | 01-28-2010 |
20100099645 | Compositions containing pufa and methods of use thereof - This invention provides methods of increasing or enhancing the synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell; methods of treating a subject with a memory disorder, memory impairment, neurological disorder, or brain disease or disorder, comprising administering to the subject a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, uridine, a metabolic precursor thereof, or a combination thereof. | 04-22-2010 |